Literature DB >> 17277353

A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland.

Niamh F Murphy1, Colin R Simpson, Pardeep S Jhund, Simon Stewart, Michelle Kirkpatrick, Jim Chalmers, Kate MacIntyre, John J V McMurray.   

Abstract

OBJECTIVE: To examine the epidemiology, primary care burden and treatment of atrial fibrillation (AF).
DESIGN: Cross-sectional data from primary care practices participating in the Scottish Continuous Morbidity Recording scheme between April 2001 and March 2002.
SETTING: 55 primary care practices (362 155 patients). PARTICIPANTS: 3135 patients with AF.
RESULTS: The prevalence of AF in Scotland was 9.4/1000 in men and 7.9/1000 in women (p<0.001) and increased with age (to 71/1000 in individuals aged >85 years). The prevalence of AF decreased with increasing socioeconomic deprivation (9.2/1000 least deprived and 7.5/1000 most deprived category, p = 0.02 for trend). 71% of patients with AF received rate-controlling medication: beta-blocker 28%, rate-limiting calcium-channel blocker 42% and digoxin 43%. 42% of patients received warfarin, 44% received aspirin and 78% received more than one of these. Multivariable analysis showed that men and women aged > or =75 years were more likely (than those aged <75 years) to be prescribed digoxin (men OR 1.41, 95% CI 1.14 to 1.74; women OR 1.88, 95% CI 1.50 to 2.37) and aspirin (2.04, 1.66 to 2.51; 1.79, 1.42 to 2.25) and less likely to receive an antiarrhythmic drug (0.62, 0.48 to 0.81; 0.52, 0.39 to 0.70) or warfarin (0.74, 0.60 to 0.91; 0.58, 0.46 to 0.73). Adjusted analysis showed no socioeconomic gradient in prescribing.
CONCLUSIONS: AF is a common condition, more so in men than in women. Deprived individuals are less likely to have AF, a finding raising concerns about socioeconomic gradients in detection and prognosis. Recommended treatments for AF were underused in women and older people. This is of particular concern, given the current trends in population demographics and the evidence that both groups are at higher risk of stroke.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277353      PMCID: PMC1955558          DOI: 10.1136/hrt.2006.107573

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  28 in total

1.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study.

Authors:  N F Murphy; C R Simpson; K MacIntyre; F A McAlister; J Chalmers; J J V McMurray
Journal:  Heart       Date:  2006-01-06       Impact factor: 5.994

3.  Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.

Authors:  Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

4.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; Alessandro Capucci; A John Camm; S Bertil Olsson; Dietrich Andresen; D Wyn Davies; Stuart Cobbe; Günter Breithardt; Jean-Yves Le Heuzey; Martin H Prins; Samuel Lévy; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2005-10-04       Impact factor: 29.983

5.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

Authors:  E J Benjamin; P A Wolf; R B D'Agostino; H Silbershatz; W B Kannel; D Levy
Journal:  Circulation       Date:  1998-09-08       Impact factor: 29.690

6.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).

Authors:  Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; José Luis Zamorano
Journal:  J Am Coll Cardiol       Date:  2006-08-15       Impact factor: 24.094

7.  Incidence of chronic atrial fibrillation in general practice and its treatment pattern.

Authors:  Ana Ruigómez; Saga Johansson; Mari Ann Wallander; Luis Alberto García Rodríguez
Journal:  J Clin Epidemiol       Date:  2002-04       Impact factor: 6.437

8.  Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care.

Authors:  S DeWilde; I M Carey; C Emmas; N Richards; D G Cook
Journal:  Heart       Date:  2005-12-30       Impact factor: 5.994

9.  Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.

Authors:  M Sudlow; R Thomson; B Thwaites; H Rodgers; R A Kenny
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

10.  Audit of populations in general practice: the creation of a national resource for the study of morbidity in Scottish general practice.

Authors:  R M Milne; M W Taylor; R J Taylor
Journal:  J Epidemiol Community Health       Date:  1998-04       Impact factor: 3.710

View more
  52 in total

1.  Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.

Authors:  Dipak Kotecha; Karina V Bunting; Simrat K Gill; Samir Mehta; Mary Stanbury; Jacqueline C Jones; Sandra Haynes; Melanie J Calvert; Jonathan J Deeks; Richard P Steeds; Victoria Y Strauss; Kazem Rahimi; A John Camm; Michael Griffith; Gregory Y H Lip; Jonathan N Townend; Paulus Kirchhof
Journal:  JAMA       Date:  2020-12-22       Impact factor: 56.272

2.  Atrial fibrillation: beware of the government gap.

Authors:  John Robson
Journal:  Br J Gen Pract       Date:  2020-08-27       Impact factor: 5.386

Review 3.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 4.  Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.

Authors:  Rohan Shah; Manesh R Patel
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-09-19

Review 5.  MicroRNAs and atrial fibrillation: mechanisms and translational potential.

Authors:  Xiaobin Luo; Baofeng Yang; Stanley Nattel
Journal:  Nat Rev Cardiol       Date:  2014-11-25       Impact factor: 32.419

Review 6.  Cardiac adrenergic control and atrial fibrillation.

Authors:  Antony J Workman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-04       Impact factor: 3.000

7.  An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality.

Authors:  Etienne Aliot; Günter Breithardt; Josep Brugada; John Camm; Gregory Y H Lip; Panos E Vardas; Markus Wagner
Journal:  Europace       Date:  2010-05       Impact factor: 5.214

Review 8.  Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Authors:  Natalie J Carter; Greg L Plosker
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

9.  Bipolar Disorder and Schizophrenia Present Different Risks of Atrial fibrillation: A Nationwide Population-Based Analysis.

Authors:  Hung-Yu Yang; Jen-Hung Huang; Yung-Kuo Lin; Chien-Yeh Hsu; Shih-Ann Chen; Yi-Jen Chen
Journal:  Acta Cardiol Sin       Date:  2014-01       Impact factor: 2.672

10.  Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians' Decision and CHA2DS2-VASc and HAS-BLED Scores.

Authors:  Marzieh Balaghi-Inalou; Saeed Alipour Parsa; Latif Gachkar; Sasan Andalib
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.